These included GPS2, negative regulator of RAS- and MAPK-mediated signal (34), recurrently mutated in prostate cancer; BRD7, member of the SWI/SNF chromatin remodeling complex, recurrently altered in urothelial cancer; GPAM, associated with steatosis and liver damage (35), recurrently mutated in liver cancer or FANCM, known susceptibility gene for breast cancer (36) but identified here as a somatic driver. This evidence concerns the gene GPS2 and prostate carcinoma.